Maridebart cafraglutide Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since June 2026

Also known as: AMG 133, MariTide

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

Amgen2

Indications

Overweight or Obesity and Elevated Liver Fat1
Heart Failure With Mildly Reduced Ejection Fraction1
Liver Disease1
Heart Failure With Preserved Ejection Fraction1
Heart Disease1

Birmingham, Alabama1 trial

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

University of Alabama Saint Vincent's Birmingham

Phase 3

Chandler, Arizona1 trial

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Arizona Clinical Trials

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.